NCT02974855View on ClinicalTrials.gov

PF-06741086 Multiple Dose Study in Severe Hemophilia

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

March 8, 2017

Primary Completion Date

December 3, 2018

Study Completion Date

December 3, 2018

Conditions
Hemophilia A or B
Interventions
BIOLOGICAL

PF-06741086

PF-06741086 subcutaneous (SC) injection

BIOLOGICAL

PF-06741086

PF-06741086 SC injection

BIOLOGICAL

PF-06741086

PF-06741086 SC injection

BIOLOGICAL

PF-06741086

PF-06741086 SC injection

Trial Locations (10)

2193

Haemophilia Comprehensive Care Centre, Johannesburg

6001

Phoenix Pharma (Pty) Ltd, Port Elizabeth

8091

UniversitatsSpital Zurich, Klinik fur Hamatologie, Zurich

10000

Klinicki bolnicki centar Zagreb, Zagreb

60612

Pharmacy, Chicago

Rush University Medical Center, Chicago

80045

UC Denver Hemophilia and Thrombosis Center - Pharmacy, Aurora

UC Denver Hemophilia and Thrombosis Center, Aurora

8207257

Hospital Dr. Sotero del Rio, Santiago

80-952

Klinika Hematologii i Transplantologii Uniwersyteckie Centrum Kliniczne, Gdansk

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT02974855 - PF-06741086 Multiple Dose Study in Severe Hemophilia | Biotech Hunter | Biotech Hunter